The potential of Viking Therapeutics (VKTX) in the weight-loss drug field may have surpassed the market’s initial expectations. Currently, numerous companies in the healthcare industry are actively developing weight-loss medications, and such products have already made a significant impact on the medical community. Viking Therapeutics recently gained attention due to a new study on the properties of GLP-1 agonist drugs, with its stock rising nearly 4% on Thursday, significantly outperforming the S&P 500 index’s 0.3% gain on the same day.
Weight-loss drugs have not only proven effective in reducing body weight but may also have positive effects on certain health conditions. This ripple effect is a key reason investors remain optimistic about related companies. A recent study suggested that GLP-1 agonists—substances that mimic the satiety hormone released after eating—may have a positive impact on hidradenitis suppurativa. This skin condition, characterized by small lumps under the skin, is challenging to treat. Research indicates that such drugs possess broad anti-inflammatory properties, offering at least potential benefits in alleviating the aforementioned symptoms.
Viking’s lead drug candidate, VK2735, is a GLP-1/GIP dual agonist, targeting not only the GLP-1 receptor but also the glucose-dependent insulinotropic polypeptide (GIP) receptor. Due to its inclusion of the GLP-1 agonist mechanism, if the conclusions of the aforementioned study hold true, VK2735 may also be applicable to patients with hidradenitis suppurativa, thereby significantly enhancing the drug’s application value and commercial prospects.
Earlier, in August of this year, Viking announced positive results from a Phase II clinical trial of the oral tablet formulation of VK2735. As a dual agonist of GLP-1 and GIP receptors, the drug is being developed in both oral and subcutaneous injection forms for the treatment of metabolic diseases such as obesity. This 13-week Phase II study met all primary and secondary endpoints: patients treated with VK2735 experienced significantly greater weight loss compared to the placebo group, with a maximum reduction of 12.2% from baseline body weight, representing a 10.9% greater reduction than the placebo group. Weight loss was progressive throughout the study without reaching a plateau, and the drug demonstrated a favorable safety and tolerability profile, with most adverse events being mild to moderate in severity.
Dr. Brian Lian, the company’s CEO, stated that these results validate VK2735’s dose response and weight-loss efficacy. The progressive weight loss trend suggests that extended treatment duration may yield additional benefits. Furthermore, preliminary data from the maintenance dose group in the trial indicated that transitioning from a high dose to a low-dose oral treatment regimen may have potential for weight maintenance. The company plans to further explore this direction in subsequent studies.
